ESPR vs MS · rev $332.3M vs P/E 20, $344.27B cap
Esperion Therapeutics Inc (ESPR) versus Morgan Stanley (MS) — a side-by-side from cached financials, not a winner call.
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Morgan Stanley (MS) is a capital markets company listed on US. It is led by Ted Pick.
Latest reported ESPR revenue for 2024-12-31 was $332.3M. Net income was -$51.7M. Revenue was up 185.7% from 2023-12-31 to 2024-12-31. ESPR currently screens at market cap $816.9M.
MS does not have a complete income-statement cache yet.
ESPR currently screens at market cap $816.9M. MS currently screens at market cap $344.27B and trailing P/E 19.8.
Not investment advice. Open the ESPR and MS stock pages for the full models.
Not investment advice.